Beam Therapeutics [BEAM] vs Vertex [VRTX] Detailed Stock Comparison
Beam Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Beam Therapeutics wins in 4 metrics, Vertex wins in 13 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Beam Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.64 | 27.77 | Beam Therapeutics |
| Price-to-Book Ratio | 1.50 | 5.83 | Beam Therapeutics |
| Debt-to-Equity Ratio | 14.79 | 8.89 | Vertex |
| PEG Ratio | 0.37 | -0.22 | Vertex |
| EV/EBITDA | -1.36 | 19.86 | Beam Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | -1,419.22% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -41.94% | 22.77% | Vertex |
| Return on Assets (TTM) | -21.02% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-356.19M | $-978.00M | Beam Therapeutics |
| 1-Year Return | -37.93% | -17.90% | Vertex |
| Price-to-Sales Ratio (TTM) | 26.87 | 8.77 | Vertex |
| Enterprise Value | $577.88M | $95.33B | Vertex |
| EV/Revenue Ratio | 9.59 | 8.35 | Vertex |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $1 | $44 | Vertex |
| Earnings per Share (Diluted) | $-4.50 | $14.07 | Vertex |
| Beta (Stock Volatility) | 2.23 | 0.44 | Vertex |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Beam Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beam Therapeutics | 3.94% | -6.62% | -22.75% | -3.48% | -45.96% | -32.63% |
| Vertex | -0.57% | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beam Therapeutics | -37.93% | -70.42% | -33.28% | -19.30% | -19.30% | -19.30% |
| Vertex | -17.90% | 40.27% | 46.36% | 194.76% | 1,046.94% | 2,164.30% |
Performance & Financial Health Analysis: Beam Therapeutics vs Vertex
| Metric | BEAM | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.62B | $100.19B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,701,040 | 2,534,760 |
| 90 Day Avg. Volume | 2,450,340 | 1,946,450 |
| Last Close | $16.64 | $395.21 |
| 52 Week Range | $13.52 - $35.25 | $362.50 - $519.88 |
| % from 52W High | -52.79% | -23.98% |
| All-Time High | $138.52 (Jun 28, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -87.99% | -23.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.28% | 0.12% |
| Quarterly Earnings Growth | -0.28% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | -14.19% | 0.39% |
| Return on Equity (TTM) | -0.42% | 0.23% |
| Debt to Equity (MRQ) | 14.79 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $10.70 | $67.02 |
| Cash per Share (MRQ) | $11.71 | $24.90 |
| Operating Cash Flow (TTM) | $-344,824,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-164,037,248 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Beam Therapeutics vs Vertex
| Metric | BEAM | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.64 | 27.77 |
| Forward P/E | -3.36 | 20.82 |
| PEG Ratio | 0.37 | -0.22 |
| Price to Sales (TTM) | 26.87 | 8.77 |
| Price to Book (MRQ) | 1.50 | 5.83 |
| Market Capitalization | ||
| Market Capitalization | $1.62B | $100.19B |
| Enterprise Value | $577.88M | $95.33B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.59 | 8.35 |
| Enterprise to EBITDA | -1.36 | 19.86 |
| Risk & Other Metrics | ||
| Beta | 2.23 | 0.44 |
| Book Value per Share (MRQ) | $10.70 | $67.02 |
Financial Statements Comparison: Beam Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BEAM | VRTX |
|---|---|---|
| Revenue/Sales | $7.47M | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $98.82M | $978.40M |
| Operating Income (EBIT) | $-119.29M | $1.15B |
| EBITDA | $-113.91M | $1.34B |
| Pre-Tax Income | $-109.27M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-109.27M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BEAM | VRTX |
|---|---|---|
| Cash & Equivalents | $527.91M | $4.67B |
| Total Current Assets | $1.25B | $10.01B |
| Total Current Liabilities | $141.55M | $3.78B |
| Long-Term Debt | $144.92M | $1.65B |
| Total Shareholders Equity | $1.12B | $16.50B |
| Retained Earnings | $-1.68B | $10.25B |
| Property, Plant & Equipment | $176.23M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BEAM | VRTX |
|---|---|---|
| Operating Cash Flow | $-81.45M | $404.90M |
| Capital Expenditures | $-3.07M | $-40.70M |
| Free Cash Flow | $-106.95M | $778.20M |
| Debt Repayment | $0 | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | BEAM | VRTX |
|---|---|---|
| Shares Short | 24.62M | 4.36M |
| Short Ratio | 10.11 | 4.04 |
| Short % of Float | 0.27% | 0.02% |
| Average Daily Volume (10 Day) | 2,701,040 | 2,534,760 |
| Average Daily Volume (90 Day) | 2,450,340 | 1,946,450 |
| Shares Outstanding | 83.63M | 256.94M |
| Float Shares | 87.02M | 255.58M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.06% | 0.99% |
Dividend Analysis & Yield Comparison: Beam Therapeutics vs Vertex
| Metric | BEAM | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |